In a report released on March 1, Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $28.00. The company’s shares closed last Friday at $26.59.
According to TipRanks, Bansal is a 4-star analyst with an average return of 9.2% and a 58.97% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Regeneron, and Amgen.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $31.18, which is a 17.26% upside from current levels. In a report released on March 1, Morgan Stanley also maintained a Hold rating on the stock with a $28.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Pfizer’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $14.25 billion and a GAAP net loss of $3.37 billion. In comparison, last year the company earned a revenue of $24.29 billion and had a net profit of $4.99 billion
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer (PFE) Company Description:
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Cardiff Oncology doses first patient in CRDF-004 trial
- Pfizer to hold Oncology Innovation Day
- Olema Pharmaceuticals (NASDAQ:OLMA) Stock: Is There More Upside After a Remarkable Run in 2023?
- Pfizer announces top-line Abrysvo vaccine efficacy and safety data
- Pfizer files automatic mixed securities shelf
